Cyclerion Therapeutics Current Ratio 2018-2021 | CYCN

Cyclerion Therapeutics current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cyclerion Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.07B $0.01B 6.95
2021-03-31 $0.04B $0.01B 3.30
2020-12-31 $0.06B $0.02B 3.45
2020-09-30 $0.07B $0.02B 4.31
2020-06-30 $0.06B $0.02B 3.81
2020-03-31 $0.07B $0.01B 6.13
2019-12-31 $0.10B $0.02B 5.55
2019-09-30 $0.12B $0.02B 6.32
2019-06-30 $0.15B $0.02B 6.60
2019-03-31 $0.00B $0.02B 0.05
2018-12-31 $0.00B $0.02B 0.05
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B $0.01B 0.09
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.116B $0.002B
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in clinical stage. Cyclerion Therapeutics Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00